Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,002

Participants

Timeline

Start Date

August 6, 2014

Primary Completion Date

May 19, 2015

Study Completion Date

May 19, 2015

Conditions
Dengue Fever
Interventions
DRUG

TDV Liquid Formulation 1

TDV Liquid Formulation 1 for subcutaneous injection

DRUG

TDV Liquid Formulation 2

TDV Liquid Formulation 2 for subcutaneous injection

DRUG

TDV IDT Lyophilized

TDV Lyophilized Formulation for subcutaneous injection

DRUG

Placebo

TDV liquid formulation placebo-matching solution for subcutaneous injection

Trial Locations (7)

30281

Clinical Research Atlanta, Stockbridge

66219

Johnson County Clin-Trials, Lenexa

78745

Tekton Research, Austin

83462

Advanced Clinical Research, Meridian

85018

Hope Research Institute, Phoenix

89104

Clinical Research Center of Nevada, Las Vegas

92805

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY